egfr-mutated
Entity, reached from Hormuz.
- Evidence
- 28 documents · 10 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 3 Sept 2026, last seen 9 Oct 2026
- Measured
- 32% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- European Medical Journal · 2026-10-09 · Multidisciplinary Perspectives on the Evolving Management of EGFR-Mutated Metastatic NSCLC (opens the source in a new tab)
- AllSci News · 2026-09-30 · AstraZeneca seeks FDA approval for HutchMed's Orpathys plus Tagrisso in MET-driven lung cancer (opens the source in a new tab)
- The ASCO Post · 2026-09-18 · Metastatic EGFR-Mutated NSCLC Global Study of Izalontamab Brenitecan (opens the source in a new tab)
- The ASCO Post · 2026-09-16 · Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC (opens the source in a new tab)
- PR Newswire · 2026-09-12 · SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026 (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with lung cancer (28 documents)seen together
- co-mentioned with egfr (28 documents)seen together
- co-mentioned with her2 (16 documents)seen together
- co-mentioned with cancer center (13 documents)seen together
- co-mentioned with her2-directed (12 documents)seen together
- co-mentioned with her3 (12 documents)seen together
- co-mentioned with iaslc (12 documents)seen together
- co-mentioned with wclc (12 documents)seen together
- co-mentioned with her2-mutant (11 documents)seen together
- co-mentioned with iiia (11 documents)seen together